Malondialdehyde in benign prostate hypertrophy: A useful marker?

Mediators of Inflammation

Volumn 12, Issue 2, 2003, Pages 127-128

  Merendino, Rosaria Alba ^a   Salvo, Francesco ^a   Saija, Antonella ^a   Di Pasquale, Giuseppe ^a   Tomaino, Antonio ^a   Minciullo, Paola Lucia ^a   Fraccica, Giuseppe ^a   Gangemi, Sebastiano ^a  

^a UNIVERSITY OF MESSINA   (Italy)

Author keywords

Benign prostate hypertrophy; Malondialdehyde; Prostate specific antigen

Indexed keywords

BIOLOGICAL MARKER; FATTY ACID ESTER; MALONALDEHYDE; POLYUNSATURATED FATTY ACID; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BENIGN TUMOR; BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; HUMAN; INFLAMMATION; LIPID PEROXIDATION; MALE; OXIDATIVE STRESS; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; UREMIA; URETHRA OBSTRUCTION;

AGED; BIOLOGICAL MARKERS; HUMANS; MALE; MALONDIALDEHYDE; MIDDLE AGED; OXIDATIVE STRESS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA;

EID: 0037789398     PISSN: 09629351     EISSN: None     Source Type: Journal    
DOI: 10.1080/0962935031000097745     Document Type: Article

References (5)

1. Wick G, Janser-Durr P, Berger P, Blasko I, Grubeck-Loebenstein B. Diseases of aging. Vaccine 2000; 18: 1567-1583.
2. Levine AC. Pathogenesis and medical management of benign prostatic hyperplasia. Trends Endocrinol Metab 1995; 6: 128-132.
3. Teillac P, Peiret C, Najean Y, Le Duc A. Prostate-specific antigen in prostatic pathology. Ann Urol (Paris) 1988; 22: 193-196.
4. Meagher EA, FitzGerald GA. Indeces of lipid peroxidation in vivo: strengths and limitation. Free Radic Biol Med 2000; 28: 1745-1750.
5. Muradian K, Schachtschabel DO. The role of apoptosis in aging and age-related disease: update. Z Gerontol Geriatr 2001; 34: 441-446.